PA
AVXL icon

Perceptive Advisors’s Anavex Life Sciences AVXL Stock Holding History

Perceptive Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-780,007
Closed -$4.21M – 144
2020
Q4 		$4.21M Buy
+780,007
New +$4.11M 0.05% 123

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GLA
Great Lakes Advisors Chicago, Illinois $13.1B AUM 34.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Perceptive Advisors's AVXL Position: Q1 2021 in Review

Perceptive Advisors sold out of Anavex Life Sciences (AVXL) in Q1 2021, closing a stake of 780,007 shares — an estimated $4.21M sold.

Perceptive Advisors first reported a position in AVXL in Q4 2020 and held it in 1 quarter. The position peaked at $4.21M in Q4 2020. 108 funds tracked by Wall St. Rank hold AVXL as of Q1 2021.

  • Perceptive Advisors reported no remaining Anavex Life Sciences position as of Q1 2021 after selling out during the quarter.
  • Perceptive Advisors sold 780,007 Anavex Life Sciences shares in Q1 2021, an estimated $4.21M.
  • Perceptive Advisors first reported a position in Anavex Life Sciences in Q4 2020 and held it in 1 quarter.
  • Perceptive Advisors's Anavex Life Sciences position peaked at $4.21M in Q4 2020.
  • 108 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2021.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.